Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER.

The effect of dapagliflozin was also consistent, regardless of PAD history, for all the other clinical outcomes examined, except for worsening HF and HF hospitalization; dapagliflozin significantly reduced the risk of these outcomes in both patients with and without PAD, but the reduction appeared to be larger in those with PAD, with nominally significant interactions between PAD status and the effect of dapagliflozin on these outcomes ( Table 3 , Figure 2 ).

also in 7,732 other papers